The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a four-year Women’s Health Programme aimed at addressing evidence gaps and improving the safety and effectiveness of medicines and medical devices used by women across the UK.
Better data, better healthcare
In his foreword, MHRA chief executive Lawrence Tallon calls for “decisive, system-wide action” to close the evidence gap for women across healthcare, warning that “small scale isolated efforts will not be sufficient”.
The MHRA’s focus on evidence gaps that affect access, confidence and outcomes throughout women’s lives echoes themes in our recent FemHealth Focus report, The data imperative, which explores how better and more representative health data can help close the gender health gap.
The figures highlight the scale of the evidence gap:
• Fewer than 1% of UK clinical trials include pregnant women, and only 0.6% include breastfeeding women.
• 33% of trials approved between 2019 and 2023 included women of childbearing potential.
• Women continue to experience differences in safety, effectiveness and adverse events.
The regulator’s four-year programme to 2030 is a welcome step towards addressing longstanding inequalities in the evidence underpinning women’s healthcare. The MHRA’s ambition is to ensure regulation keeps pace with new evidence and supports responsible, appropriate innovation to improve the health of women.
Closing the evidence gap
A central focus of the MHRA’s programme is the longstanding underrepresentation of women in clinical research and the resulting gaps in the evidence underpinning medicines and medical devices.
The regulator says that it will standardise the submission of data broken down by sex throughout a product’s lifecycle and introduce guidance to assess and monitor sex-based differences both before and after authorisation.
It also plans to support greater use of regulatory pathways to address unmet needs and develop clear frameworks and guidance for the development, availability and regulatory compliance of FemTech and other women’s health technologies.
It is contributing to revisions of the International Council for Harmonisation’s E21 guideline on including pregnant and breastfeeding women in clinical trials and is analysing responses to its UK consultation on the proposals.
These commitments matter because the consequences of evidence gaps extend well beyond clinical research. They can affect how medicines, medical devices and femtech innovations are developed and approved, as well as the treatment options and choices available to healthcare professionals and patients.
Unlocking the femtech opportunity
The MHRA sees tackling the women’s health evidence gap not only as an issue of equality, but as a “powerful opportunity” to improve the evidence, standards and innovations shaping women’s healthcare throughout their lives. This includes embedding women’s health considerations from the outset in the development, assessment, monitoring and communication of healthcare products.
The economic case is significant. Closing the women’s health gap could add at least £36 billion each year to the UK economy, while the UK’s expanding femtech sector already generates annual turnover of nearly £300 million and has attracted £544 million in investment.
Together, these figures underline the opportunity. Better evidence and an effective regulatory environment have the potential not only to improve women’s health outcomes, but also to create the conditions for investment, innovation and growth in women’s health and femtech.
Looking ahead
The MHRA programme is important not because it provides an immediate solution to the women's health evidence gap, but because it begins to embed women’s health and sex-specific evidence more firmly within the regulatory lifecycle for healthcare products.
The challenge over the next four years will be turning that ambition into practical change while maintaining an environment in which responsible innovation can flourish.
Closing the evidence gap will require action across research, regulation, technology and healthcare delivery.
For healthcare providers, technology businesses, life sciences organisations and investors, that makes this an area worth watching closely.
The strategy confirms that, as part of its UK health system alignment, the regulator is working with the DHSC to align its programme with England’s renewed women’s health strategy, alongside related work in Scotland, Wales and Northern Ireland.
How we can help
Our women’s health and technology team advises organisations, innovators and investors across the sector on healthcare regulation, digital health and AI, data and privacy, medical devices, commercial arrangements, investment and routes to market.
If you are developing, investing in or bringing a women’s health product or technology to market, or want to understand how the changing regulatory landscape could affect your organisation, please get in touch with a member of our team.
Our content explained
Every piece of content we create is correct on the date it’s published but please don’t rely on it as legal advice. If you’d like to speak to us about your own legal requirements, please contact one of our expert lawyers.